INTRODUCTION

AL amyloidosis is a clonal plasma cell disorder in which excessive
Ig light chains are produced and form amyloid fibrillar deposits in, for example, heart, kidney and liver that eventually lead to organ failure and death. Especially in patients with heart involvement, mortality is high owing to progressive heart failure and arrhythmia. 1 The prognosis is poor; untreated and also when treated with oral melphalan and prednisone, survival is about 1-2 years. In patients with symptomatic cardiac amyloidosis, median survival without treatment is only 6 months. Involvement of multiple organs is also a poor prognostic sign. 2 Because of the organ dysfunction, patients with AL amyloidosis are sensitive to the toxic effects of chemotherapy, which may limit the treatment possibilities.
Treatment with high-dose melphalan and autologous stem cell transplantation (HDM/ASCT) has resulted in prolonging survival to 4-6 years, but the benefit is debated mainly because of the high treatment-related mortality that has been around 15%. [3] [4] [5] [6] [7] The advantage with HDM/ASCT could also be overestimated because of selection bias, although a case-control study with 63 AL patients undergoing HDM/ASCT and 63 matched controls showed longer survival for the patients treated with HDM/ASCT, with 4-year overall survival rates of 71% compared with 41%. 8 In one randomised study, HDM/ASCT was not shown to be superior to standard-dose melphalan plus high-dose dexamethasone, 7 however, patient selection for HDM/ASCT was not optimal in that study and treatment-related mortality was high (24%). If prognostic markers such as cardiac troponins and NT-proBNP are used to select patients for HDM/ASCT, outcome can be improved. 9 In Sweden, patients with AL amyloidosis have been treated with HDM/ASCT since 1994, but no evaluation of the outcome has been made previously, and it is not known whether the increased knowledge about, for example, patient selection has improved the results in our country. The purpose of this retrospective study was to examine the long-term outcome of HDM/ASCT in Sweden for the first 16 years since the treatment was introduced, and whether the results have changed over time.
SUBJECTS AND METHODS
Data were collected retrospectively on all patients treated with HDM/ASCT from 1994 until 2009 through contacts at the eight centres in Sweden where the treatment was performed. Follow-up was ended in April 2014. The study was performed with approval of the local Ethics Committee. Only patients with amyloid classified as AL were included. Patients with AL amyloidosis associated with lymphoma or symptomatic myeloma, and those with only soft-tissue involvement were excluded. Symptomatic myeloma was defined as 10% or more plasma cells in the bone marrow and skeletal changes, or other CRAB criteria attributable to myeloma.
Criteria from the 10th International Symposium on Amyloid and Amyloidosis were used to establish organ involvement, response and progression. 10 The aim was to collect data from diagnosis, at admission for HDM/ASCT, 3 months, 6 months, 1 year and 2 years after HDM/ASCT, at best response and at progression. Although in many patients, data from all these occasions were not available.
The majority of patients were treated in a time period when free light chain analysis was not in clinical use. Only in 16 of the 72 patients (22%), was free light chain analysis available for follow-up.
IBM SPSS version 21 (Armonk, NY, USA) was used for statistical analyses. Survival was estimated using Kaplan-Meier Analysis, and the log-rank test was used to evaluate differences between survival curves. The χ 2 -test was used to compare categorical variables. Fifty-two per cent had elevated plasma cells (3% or more) in the bone marrow, with a median plasma cell count of 7.3%. Forty-one per cent had M-protein in the blood with a median level of 8 g/L and 48% had measurable Bence Jones proteinuria (median 110 mg/L).
RESULTS
Seventy
Fifty-seven patients (79%) had kidney involvement, 29 (40%) had cardiac involvement and 17 (24%) had liver involvement. In six patients (8%), all three of these organs were involved, in 22 patients (31%), two of the organs were involved and in 41 patients (57%), one of the organs was involved. In three patients (4%), none of these three organs was involved, these patients had only gastrointestinal involvement.
In the patients with renal involvement, the median 24 h urine albumin was 5125 mg per day (range 505-27 300). The patients with heart involvement had a median cardiac wall thickness of 16.5 mm (range [13] [14] [15] [16] [17] [18] [19] [20] .
Twenty-four patients (36%) had received induction treatment before HDM/ASCT; VCR/adriamycin/dexamethasone (n = 10), cyclophosphamide/dexamethasone (n = 6), melphalan/prednisone (n = 4), VCR/adriamycin/cyclophosphamide/prednisone (n = 3), only steroids (n = 2) and cyclophosphamide/VCR/prednisone (n = 1). Stem cells were mobilised with G-CSF alone (69%, n = 50), cyclophosphamide and G-CSF (28%, n = 20) or other regimens (3%, n = 2). In all except two patients, HDM/ASCT was performed as part of primary therapy. The remaining two patients were initially treated with oral melphalan and prednisone with insufficient response.
The given dose of melphalan was 200 mg/m 2 in 41 patients (57%), 160 mg/m 2 in 1 patient (1%), 140 mg/m 2 in 18 patients (25%), 120 mg/m 2 in 1 patient (1%) and 100 mg/m 2 in 11 patients (15%). The reasons for dose reduction are not known.
The median time from diagnosis to HDM/ASCT was 5.5 months (range 2-126) for the patients that were treated before HDM/ASCT and 3 months (range 1-29) for the patients who did not receive induction treatment.
Response (at least partial response), either organ or haematological, was seen in 46 patients (64%); 41 patients (57%) had organ response and 5 patients (7%) had only haematological response. Median time to response was 4 months (range 1-16).
Median event-free survival, measured from the time of SCT until progression (organ or haematological) or death, was 41 months (range 0-175; Figure 1 ).
Treatment at progression was melphalan/prednisone or dexamethasone (n = 10), velcade/dexamethasone (n = 8), thalidomide (n = 4), VCR/adriamycin/dexamethasone (n = 2), only steroids (n = 2), cyclophosphamide/velcade/dexamethasone (n = 1), cyclophosphamide/thalidomide/dexamethasone (n = 1) and velcade/ melphalan/dexamethasone (n = 1). Eight patients were not treated at progression.
Indication for treatment could be either organ or haematological progression.
Five patients underwent a second HDM/ASCT, in all cases at first progression after the initial HDM/ASCT. Median time between the first and second HDM/ASCT was 9.8 years (range 1.5-10.3). Four out of the five patients achieved at least partial response after the second HDM/ASCT. Three of these patients have received treatment again after the second HDM/ASCT, after a period of 6.5, 2.1 and 2.1 years, respectively, and in the fourth patient, disease progression has not occurred 1. compared with 56 months in patients with two or more involved organs, P = 0.009 ( Figure 3 ). There was no significant difference in survival between the patients who had received treatment before HDM/ASCT and those who had not. Median survival for patients who received a higher dose of melphalan (160-200 mg/m 2 ) was 124 months compared with 82 months with a lower dose (100-140 mg/m 2 ), but the difference was NS, P = 0.175.
Mortality within 100 days from ASCT was 12.5% for all patients. Causes of death were sudden cardiac death (n = 3), heart failure (n = 3) and infection (n = 3). Half of the patients that died from cardiac causes had received induction treatment. All complications that were considered treatment-related are listed in Table 1 .
For patients with heart involvement, 100-day mortality was higher than for those without heart involvement, 17.2% compared with 9.3% (NS). Patients treated in the earlier period (1994-2001) also had higher mortality the first 100 days, 23.8% compared with 7.8% (NS) in the later period (2002-2009). The proportion of patients with cardiac amyloidosis or involvement of two or more organs did not differ significantly between the earlier and later time period.
Six patients have received a kidney transplant. Four of them received the transplant after HDM/ASCT and one of them before. In one of the patients, kidney transplantation was performed directly prior to a second HDM/ASCT. Five of the six patients receiving renal transplants are alive, and not on dialysis, with a median follow-up of 140 months (11.7 years). The sixth patient died in disease progression 4.5 years after HDM/ASCT.
Two patients have received a heart transplant, one before and one after HDM/ASCT, both these patients died (2.5 and 4.5 years after the heart transplant).
The number of patients treated with HDM/ASCT during the studied 16-year period varied between 5 and 11 per million inhabitants in the different regions of the country. During the studied period, between 0 and 11 patients were treated per year, with a tendency towards fewer patients in the later years ( Figure 4 ).
DISCUSSION
This study shows that HDM/ASCT, to a substantial degree, leads to response and, in some patients, long-term remission is achieved. The response rate of 64% is comparable to results reported previously. 4, 11 Overall median survival for the whole patient group was 98 months (8.2 years), with the longest surviving patient being alive 19 years after treatment. Five-and 10-year overall survival was 64% and 43%, respectively. These results are notably good considering that treatment was performed in relatively small centres not specialised in amyloidosis, and includes patients treated in a period when experience with HDM/ASCT in AL amyloidosis was limited. A small number of patients received a second HDM/ASCT, most of them achieved a long remission after the second treatment as well.
For patients with cardiac involvement, survival is worse, with a median survival of only 49 months. Mortality within 100 days from HDM/ASCT is also higher in this group (17.2%). The degree of cardiac dysfunction has been shown to be one of the most important prognostic factors for survival in AL amyloidosis and outcome after HDM/ASCT, and can be assessed by markers such as NT-proBNP and cardiac troponins. 12, 13 These markers are now used in staging systems for AL amyloidosis and in the selection of patients for HDM/ASCT, to reduce the transplant-related mortality. This study includes patients treated in a time period when cardiac markers were not used, and therefore patients with substantial cardiac dysfunction were probably treated.
Patients with involvement of two or more organs also have worse survival (median 56 months). Previous studies have shown that the number of organs involved is an important prognostic factor, with higher number of organs involved being associated with shorter survival times and higher mortality after treatment with HDM/ASCT. 4, 5 It has been suggested that the number of organs involved should be included in a staging system for risk assessment, but this has been questioned because of the diversity in how the number of organs is counted and the belief that the degree of organ dysfunction is more important. 9 It has earlier been shown that induction therapy result in a substantial number of deaths prior to HDM/ASCT, but reduced transplant-related mortality.
14 In this study however, treatment before HDM/ASCT was not associated with significantly better survival. And early cardiac death was not more common among the patients that had not received induction treatment.
Many patients (42%) in this study received a reduced dose of melphalan. It has been shown earlier that dose reduction of melphalan (to reduce transplant-related toxicity) is related to lower response rates. 15 In this study, dose reduction was not associated with shorter survival that was statistically significant.
The high 100-day mortality (12.5%) in this study is on a level with what is reported by others. [3] [4] [5] [6] For patients treated during the later part of the period, the early mortality was lower, 7.8% compared with 23.8% in the earlier period, although the difference was not statistically significant possibly owing to small patient groups. Other studies have shown improved outcomes in the later years, with higher response rate, lower early mortality (to around 5%) and longer overall survival. 16, 17 This is probably owing to better selection of patients for HDM/ASCT, and improvements in the transplant procedures and supportive care. Unfortunately, this does not seem to apply for patients with cardiac amyloidosis. A recent report on 1536 patients from the Center for International Blood and Marrow Transplant Research database could not show any statistically significant improvement in survival over time for patients with heart involvement. 17 In this study, six patients underwent organ transplantation, which was performed either before or after HDM/ASCT. This reflects the fact that it is not known which sequence is superior. In one retrospective study with 19 AL patients who underwent kidney transplantation, no significant difference in graft or patient survival was seen when HDM/ASCT was performed before compared with after kidney transplantation. Recurrence of AL amyloidosis in the kidney graft did also not differ significantly between the groups. 18 Considering the varying frequency of HDM/ASCT between the regions of the country, different criteria for treatment have probably been used. There is a need for more coherence when it comes to selecting patients for SCT and also in the follow-up routines.
In summary, this study shows that good results can be obtained treating AL amyloidosis with HDM/ASCT, also in small centres. Early mortality is high, but with a decreasing trend. In cardiac amyloidosis, prognosis is still poor, and there is a need for safer therapy and also earlier diagnosis in this group.
